Abstract
OBJECTIVE: Preferential IGF-1Ec expression has been firmly associated with skeletal muscle repair mechanisms, post-infarction remodeling of the myocardium, the pathophysiology of endometriosis and prostate cancer biology. Therefore, we have studied the possible biological significance of synthetic Ec peptide, a putative cleavage product of IGF-1Ec in PC-3 cells and C2C12 myoblasts. DESIGN: We had previously designed and synthesized commercially peptides corresponding to the human Ec and its mouse igf1 counterpart as well as synthetic peptides that correspond to parts of the hEc. Using proliferation and mitogenic signaling assays, we tested their effect on PC-3 cells and C2C12 myoblasts at different doses and in different culture conditions. RESULTS: Human Ec, hEc, was documented as exerting progression but not competence growth factor actions, activating ERK1/2 without affecting Akt phosphorylation in PC-3 cells. A narrow concentration range of hEc (5–50nM) stimulated the growth of PC-3 cells grown in culture media supplemented with 10% FBS. hEc did not stimulate the growth of PC-3 cells cultured with media containing 0.5% FBS or in mouse C2C12 myoblasts under any culture conditions. The activity of hEc was blocked by a neutralizing anti-human IGF-1Ec antibody but not by a neutralizing anti-human IGF-1 receptor antibody. The synthetic mouse Ec was inactive in human PC-3 cells; however, it stimulated significantly the proliferation of mouse C2C12. By analyzing the bioactivity of synthetic hEc fragments, we documented that hEc’s active core is located in the last 4aa of its C-terminal end. CONCLUSION: The hEc peptide is an important progression factor for human PC-3 prostate cancer cells.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baker J, Hardy MP, Zhou J, 1996 Effects of an Igf1 gene null mutation on mouse reproduction. Mol Endocrinol 10: 903–918.
Philippou A, Halapas A, Maridaki M, Koutsilieris M, 2007 Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact 7: 208–218.
Philippou A, Maridaki M, Pneumaticos S, Koutsilieris M, 2014 The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity. Mol Med 20: 202–214.
Ma QL, Yang TL, Yin JY, et al, 2009 Role of insulin-like growth factor-1 (IGF-1) in regulating cell cycle progression. Biochem Biophys Res Commun 389: 150–155.
Mairet-Coello G, Tury A, DiCicco-Bloom E, 2009 Insulin-like growth factor-1 promotes G(1)/S cell cycle progression through bidirectional regulation of cyclins and cyclin-dependent kinase inhibitors via the phosphatidylinositol 3-kinase/Akt pathway in developing rat cerebral cortex. J Neurosci 29: 775–788.
Armakolas A, Philippou A, Panteleakou Z, et al, 2010 Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells. Prostate 70: 1233–1242.
Siegfried JM, Kasprzyk PG, Treston AM, Mulshine JL, Quinn KA, Cuttitta F, 1992 A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone. Proc Natl Acad Sci U S A 89: 8107–8111.
Gilmour RS, 1994 The implications of insulin-like growth factor mRNA heterogeneity. J Endocrinol 140: 1–3.
Kuo YH, Chen TT, 2002 Novel activities of pro-IGF-I E peptides: regulation of morphological differentiation and anchorage-independent growth in human neuroblastoma cells. Exp Cell Res 280: 75–89.
Philippou A, Armakolas A, Panteleakou Z, 2011 IG-F1Ec expression in MG-63 human osteoblast-like osteosarcoma cells. Anticancer Res 31: 4259–4265.
Mills P, Dominique JC, Lafreniere JF, Bouchentouf M, Tremblay JP, 2007 A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. American journal of transplantation. Am J Transplant 7: 2247–2259.
Collins JM, Goldspink PH, Russell B, 2010 Migration and proliferation of human mesenchymal stem cells is stimulated by different regions of the mechano-growth factor prohormone. J Mol Cell Cardiol 49: 1042–1045.
Deng M, Zhang B, Wang K, 2011 Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. Int Orthop 35: 1099–1106.
Mills P, Lafreniere JF, Benabdallah BF, El Fahime el M, Tremblay JP, 2007 A new pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain of the mechano growth factor. Exp Cell Res 313: 527–537.
Philippou A, Papageorgiou E, Bogdanis G, 2009 Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In vivo 23: 567–575.
Milingos DS, Philippou A, Armakolas A, et al, 2011 Insulinlike growth factor-1Ec (MGF) expression in eutopic and ectopic endometrium: characterization of the MGF E-peptide actions in vitro. Mol Med 17: 21–28.
Chew SL, Lavender P, Clark AJ, Ross RJ, 1995 An alternatively spliced human insulin-like growth factor-I transcript with hepatic tissue expression that diverts away from the mitogenic IBE1 peptide. Endocrinology 136: 1939–1944.
Philippou A, Armakolas A, Koutsilieris M, 2013 Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer. Front Endocrinol (Lausanne) 4: 31.
Sawani A, Petraki C, Msaouel P, Diamanti E, Xoxakos I, Koutsilieris M, 2013 IGF-IEc expression is associated with advanced clinical and pathological stage of prostate cancer. Anticancer Res 33: 2441–2445.
Armakolas A, Kaparelou M, Dimakakos A, 2015 Oncogenic Role of the Ec Peptide of the IGF-1Ec Isoform in Prostate Cancer. Mol Med 21: 167–179.
Fornaro M, Hinken AC, Needle S, et al, 2014 Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab 306: E150–156.
Philippou A, Stavropoulou A, Sourla A, et al, 2008 Characterization of a rabbit antihuman mechano growth factor (MGF) polyclonal antibody against the last 24 amino acids of the E domain. In vivo 22: 27–35.
Papageorgiou E, Pitulis N, Manoussakis M, Lembessis P, Koutsilieris M, 2008 Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med 14: 403–411.
Koutsilieris M, Mastrogamvrakis G, Lembessis P, Sourla A, Miligos S, Michalas S, 2001 Increased insulin-like growth factor 1 activity can rescue KLE endometrial-like cells from apoptosis. Mol Med 7: 20–26.
Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ, Pledger WJ, 1979 Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci U S A 76: 1279–1283.
Lin VK, Ortwerth BJ, 1983 Competence and progression growth factors stimulate different tRNAlys modification reactions in BALB/C 3T3 cells. Biochem Biophys Res Commun 115: 598–605.
Stiles CD, 1985 The biological role of oncogenes—insights from platelet-derived growth factor: Rhoads Memorial Award lecture. Cancer Res 45: 5215–5218.
Braun-Dullaeus RC, Mann M J, Dzau VJ, 1998 Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98: 82–89.
Gerard C, Goldbeter A, 2015 Dynamics of the mammalian cell cycle in physiological and pathological conditions. Wiley Interdiscip Rev Syst Biol Med 8: 140–156.
McKoy G, Ashley W, Mander J, 1999 Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol 516: 583–592.
Hameed M, Lange KH, Andersen JL, et al, 2004 The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol 555: 231–240.
Goldspink G, 2004 Age-related loss of skeletal muscle function; impairment of gene expression. J Musculoskelet Neuronal Interact 4: 143–147.
Pena JR, Pinney JR, Ayala P, Desai TA, Goldspink PH, 2015 Localized delivery of mechano-growth factor E-domain peptide via polymeric micro structures improves cardiac function following myocardial infarction. Biomaterials 46: 26–34.
Philippou A, Barton ER, 2014 Optimizing IGF-I for skeletal muscle therapeutics. Growth Horm IGF Res 24: 157–163.
Bikle DD, Tahimic C, Chang W, Wang Y, Philippou A, Barton ER, 2015 Role of IGF-I signaling in muscle bone interactions. Bone 80: 79–88.
Brisson BK, Barton ER, 2013 New Modulators for IGF-I Activity within IGF-I Processing Products. Front Endocrinol (Lausanne) 4: 42.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papageorgiou, E., Philippou, A., Armakolas, A. et al. The human Ec peptide: the active core of a progression growth factor with species-specific mode of action. Hormones 15, 423–434 (2016). https://doi.org/10.14310/horm.2002.1699
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1699